CURX (Curanex Pharmaceuticals) EBIT per Share: $-0.26 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CURX Curanex Pharmaceuticals Inc CURX
12 GF Score
Price $0.21
View Full Analysis

What is Curanex Pharmaceuticals EBIT per Share?

Curanex Pharmaceuticals CURX +7.43% 12 EBIT per Share is $-0.26 as of Mar. 2026. GuruFocus rates CURX with a GF Score™ of 12/100. Among 1,172 Biotechnology companies, Curanex Pharmaceuticals ranks worse than 85324.15% on this metric.

Curanex Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2026 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Curanex Pharmaceuticals's EBIT per Share or its related term are showing as below:

CURX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Curanex Pharmaceuticals's EBIT for the three months ended in Mar. 2026 was $-3.15 Mil.

Curanex Pharmaceuticals  (NAS:CURX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Curanex Pharmaceuticals EBIT per Share Related Terms

Curanex Pharmaceuticals EBIT per Share Historical Data

* Premium members only.

The historical data trend for Curanex Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curanex Pharmaceuticals EBIT per Share Chart

Curanex Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT per Share
0.00 0.00 -0.01 -0.17

Curanex Pharmaceuticals Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.00 -0.04 -0.11 -0.11
CURX
12GF Score
Curanex Pharmaceuticals Inc CURX
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curanex Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Curanex Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.217/25.497
=-0.17

Curanex Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.15/28.345
=-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.26 mean?
Curanex Pharmaceuticals (CURX) has a EBIT per Share of $-0.26 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curanex Pharmaceuticals and its competitors. According to the industry distribution chart, Curanex Pharmaceuticals ranks #999999 out of 1172 companies in the Biotechnology industry.
Is Curanex Pharmaceuticals' EBIT per Share too high?
Curanex Pharmaceuticals' current EBIT per Share is $-0.26. Based on the distribution chart, Curanex Pharmaceuticals ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' EBIT per Share compare to DRMA and NCNA?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #999999 out of 1172 companies for EBIT per Share. This places Curanex Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curanex Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curanex Pharmaceuticals's current EBIT per Share is $-0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current EBIT per Share of $-0.26. The current EBIT per Share is $-0.26. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current EBIT per Share is $-0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curanex Pharmaceuticals Business Description

Address 2 Jericho Plaza, B Wing, Suite 101, Jericho, NY, USA, 11753
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score

Get the complete analysis for CURX

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price